100% Secure Payments
Tender Details
- Country: Germany
- Summary: Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Tezepelumab, Atc R03dx11 for the Period June 1St, 2023 - May 31St, 2025
- KZT Ref No: 82000125
- Deadline: 05 Apr 2025
- Competition: ICB
- Financier: Self Financed
- Purchaser Ownership: Public
- Tender Value: 1.00
- Notice Type: Tender
- Document Ref. No.: 238763-2023
- Purchaser's Detail :
- Description :
- ยง 130a paragraph 8 SGB V enables the health insurance companies and pharmaceutical companies to conclude framework discount agreements for the drugs to be supplied at the expense of the statutory health insurance companies. With regard to the relevant statutory provisions on the award of public contracts, findet a regular process of active substance-related, formal award procedures according to the regulations of the 4th part of the GWB by the DAK-Gesundheit. For pharmaceuticals to be specified by the bidder in Annex 2 to the contract for the above-mentioned The active ingredient Tezepelumab, ATC R03DX11, is intended by DAK-GesunThe aim is to conclude drug discount agreements with as many interested pharmaceutical companies as possible before new drug discount agreements come into force. A discount agreement in the context of the admission model for the above Active substance comes into force for the first time on 06/01/2023 and ends on 05/31/2025. Heregardless of this, ends automatically when the exclusive contract comes into force.
Doc Title: Pharmaceutical products
Contract Type: Supplies - Documents :
Purchaser : DAK HEALTH
Address : Nagelsweg 27-31
Town : Hamburg
NUTS-Code : DE600 - Hamburg
Postal Code : 20097
Phone : 49 402364855-2681
Fax : 49 4033470-900200
Email :vergabestelle@dak.de
URL :www.dak.de
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGIN
